Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 2017, 7021071

Efficacy of Memantine in Schizophrenic Patients: A Systematic Review

Affiliations
Review

Efficacy of Memantine in Schizophrenic Patients: A Systematic Review

Giuseppe Di Iorio et al. J Amino Acids.

Abstract

Several evidences support the hypothesis that glutamatergic dysfunction may be implicated in the pathogenesis of schizophrenia and in the last few years great interest has been focused on the role of the N-methyl-D-aspartate receptor (NMDAR). Glutamate is the main excitatory neurotransmitter in human CNS and it plays a prominent role in synaptic plasticity, learning, and memory and other cognitive functions. Increasing interest in memantine add-on therapy in schizophrenic patients with negative and cognitive symptoms may suggest that memantine could be a new promising treatment in schizophrenia. The aim of this update was to evaluate clinical data about the memantine effectiveness in schizophrenic patients. Our systematic review of the literature highlights that memantine therapy in schizophrenic patients seems to improve mainly negative symptoms while positive symptoms and cognitive symptoms did not improve significantly.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Flowchart of the systematic review.

Similar articles

See all similar articles

Cited by 5 PubMed Central articles

References

    1. Matrisciano F., Tueting P., Dalal I., et al. Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology. 2013;68:184–194. doi: 10.1016/j.neuropharm.2012.04.013. - DOI - PMC - PubMed
    1. Rapoport J. L., Giedd J. N., Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Molecular Psychiatry. 2012;17(12):1228–1238. doi: 10.1038/mp.2012.23. - DOI - PMC - PubMed
    1. Olney J. W., Farber N. B. Glutamate receptor dysfunction and schizophrenia. Archives of General Psychiatry. 1995;52(12):998–1007. - PubMed
    1. Balu D. T. Advances in Pharmacology. 1st. Elsevier; 2016. The NMDA receptor and schizophrenia: from pathophysiology to treatment; pp. 351–382. (Neuropsychopharmacology: A Tribute to Joseph T. Coyle). - DOI - PMC - PubMed
    1. Merritt K., McGuire P., Egerton A. Relationship between glutamate dysfunction and symptoms and cognitive function in psychosis. Frontiers in Psychiatry. 2013;4, article 151 doi: 10.3389/fpsyt.2013.00151. - DOI - PMC - PubMed

LinkOut - more resources

Feedback